CART-BCMA

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameCART-BCMA
Drug Alias NameCART-BCMAMTV-273
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Pennsylvania Clinical Cell and Vaccine Production FacilityUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A